Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers

por Davenport, Adam J., Neagoe, Ioana, Bräuer, Nico, Koch, Markus, Rotgeri, Andrea, Nagel, Jens, Laux-Biehlmann, Alexis, Machet, Frederic, Coelho, Anne-Marie, Boyce, Susan, Carty, Nikisha, Gemkow, Mark J., Hess, Stephen D., Zollner, Thomas M., Fischer, Oliver M.
Publicado 2021

Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069

por Orsi, Douglas L., Pook, Elisabeth, Bräuer, Nico, Friberg, Anders, Lienau, Philip, Lemke, Christopher T., Stellfeld, Timo, Brüggemeier, Ulf, Pütter, Vera, Meyer, Hanna, Baco, Maria, Tang, Stephanie, Cherniack, Andrew D., Westlake, Lindsay, Bender, Samantha A., Kocak, Mustafa, Strathdee, Craig A., Meyerson, Matthew, Eis, Knut, Goldstein, Jonathan T.
Publicado 2022

Correction to “Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069”

por Orsi, Douglas L., Pook, Elisabeth, Bräuer, Nico, Friberg, Anders, Lienau, Philip, Lemke, Christopher T., Stellfeld, Timo, Brüggemeier, Ulf, Pütter, Vera, Meyer, Hanna, Baco, Maria, Tang, Stephanie, Cherniack, Andrew D., Westlake, Lindsay, Bender, Samantha A., Kocak, Mustafa, Strathdee, Craig A., Meyerson, Matthew, Eis, Knut, Goldstein, Jonathan T.
Publicado 2022